Multicell Techs Financials
We recommend to make use of Multicell Techs fundamental analysis to find out if markets are presently mispricing the entity. Strictly speaking this technique allows you to check out available financial ratios of Multicell Techs as well as the relationship between them. We were able to analyze and collect data for twenty-four available fundamentals for Multicell Techs, which can be compared to its peers in the industry.
Multicell |
Understanding current and past Multicell Techs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Multicell Techs' financial statements are interrelated, with each one affecting the others. For example, an increase in Multicell Techs' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Multicell Techs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Multicell Techs. Check Multicell Techs' Beneish M Score to see the likelihood of Multicell Techs' management manipulating its earnings.
Multicell Techs Stock Summary
Multicell Techs competes with Brainsway, Venus Concept, Tactile Systems, Icecure Medical, and SurModics. MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island. Multicell Techs operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US62544S2005 |
| Business Address | 68 Cumberland Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.multicelltech.com |
| Phone | 401 762 0045 |
| Currency | USD - US Dollar |
Multicell Techs Key Financial Ratios
Multicell Techs' financial ratios allow both analysts and investors to convert raw data from Multicell Techs' financial statements into concise, actionable information that can be used to evaluate the performance of Multicell Techs over time and compare it to other companies across industries.| Return On Asset | -1.36 | |||
| Beta | -7.77 |
Multicell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Multicell Techs's current stock value. Our valuation model uses many indicators to compare Multicell Techs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Multicell Techs competition to find correlations between indicators driving Multicell Techs's intrinsic value. More Info.Multicell Techs is rated below average in return on asset category among its peers. It is rated below average in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Multicell Techs' earnings, one of the primary drivers of an investment's value.Multicell Techs Systematic Risk
Multicell Techs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Multicell Techs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Multicell Techs correlated with the market. If Beta is less than 0 Multicell Techs generally moves in the opposite direction as compared to the market. If Multicell Techs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Multicell Techs is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Multicell Techs is generally in the same direction as the market. If Beta > 1 Multicell Techs moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for Multicell Pink Sheet Analysis
When running Multicell Techs' price analysis, check to measure Multicell Techs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Multicell Techs is operating at the current time. Most of Multicell Techs' value examination focuses on studying past and present price action to predict the probability of Multicell Techs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Multicell Techs' price. Additionally, you may evaluate how the addition of Multicell Techs to your portfolios can decrease your overall portfolio volatility.